Evaluating colchicine's effect on knee and hip replacements in osteoarthritis patients
Official title: The Effect of ColcHicine on the Incidence of Knee or Hip Replacements: a Randomized, Double-blind, Multicentre Study in Symptomatic Knee or Hip Osteoarthritis
Run by Sint Maartenskliniek · NCT06578182 · Data updated 2026-11-12
This study is testing if taking colchicine every day can help people with osteoarthritis avoid needing knee or hip replacement surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 45 Years to 80 Years |
| Sex | All |
| Enrollment | 1410 (estimated) |
| Sponsor | Sint Maartenskliniek Academic / other |
| Locations | 1 site (Nijmegen) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | March 31, 2029 |
| Study ends | March 31, 2029 |
| Registry record updated | February 20, 2025 |
| Trial ID | NCT06578182 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 45 to 80 with a clinical diagnosis of knee or hip osteoarthritis and documented radiographic changes.
✕Probably not a fit
Patients who are on a waiting list for joint replacement surgery or have had multiple previous replacements may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to assess whether daily treatment with colchicine can reduce the incidence of knee or hip replacements in patients diagnosed with osteoarthritis. Participants will take colchicine or a placebo for a duration of 3 to 4.5 years, with regular clinic visits for check-ups, blood tests, and x-rays. The study will compare the outcomes of those receiving colchicine against those receiving a placebo to determine its effectiveness in managing osteoarthritis symptoms and preventing surgical interventions.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the need for knee and hip replacement surgeries in osteoarthritis patients.
How similar studies have gone: Previous studies have shown promising results with colchicine in other inflammatory conditions, but this specific application in osteoarthritis is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical diagnosis of knee or hip OA * 45 ≤ age ≤ 80 (upper age limit is similar to that in the LoDoCo2 trial and takes in consideration the lower number of joint replacements in people older than 80 years) * documented radiographic changes typical for advanced knee/hip OA (Kellgren \& Lawrence score ≥ 2), or at least 2-year history of complaints due to OA in the hip and/or knee Exclusion Criteria: * On a waiting list for primary joint replacement surgery of the hip or knee, irrespective of cause * Any absolute contraindication for knee or hip replacement in the future * More than one previous hip or knee replacements * Other known medical disease that may affect joints * Known generalized pain syndromes such as fibromyalgia * Renal impairment as evidenced by serum creatinine \>150µmol/l or estimated glomerular filtration rate (eGFR) \<50mL/min/1.73m2 * Liver function impairment as evidenced by serum alanine transferase (ALAT) \> 3 ULN (upper limit of normal) * Blood dyscrasia * High frailty (clinical frailty scale ≥ 7) or predicted life expectancy \< 5 years * Peripheral neuritis, myositis or marked myo-sensitivity to statins * Current use of colchicine for another indication * Intolerance to colchicine * use of macrolide antibiotics (i.e. clarithromycin, erythromycin, azithromycin), antimycotics (i.e. ketoconazole, itraconazole and voriconazole), protease inhibitors \& anti-retroviral drugs (i.e. ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (i.e. verapamil, diltiazem), or immunosuppressant (i.e. cyclosporine) * Current enrollment in another trial * Incapacitated patients * Pregnant or breastfeeding female * Fertile female participants not taking sufficient anti-conception * Male participants unwilling to use effective contraception during the study to prevent pregnancy
Where it's running
-
Sint Maartenskliniek
Nijmegen, Netherlands Recruiting
Study contacts
- Study coordinator: Tim Massa
- Email: t.massa@maartenskliniek.nl
- Phone: +31633036353
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing barbed and conventional wound closure after hip or knee replacement
This study will test whether barbed sutures or conventional sutures lead to better wound healing and fewer complications for adults having primary or aseptic revision hip or knee replacement.
-
Personalized rehabilitation care for joint replacement patients
This study is testing whether an AI tool can help create personalized rehab plans for people recovering from hip and knee joint replacement surgeries.
-
Improving sleep to reduce pain after joint surgery
This study is testing if helping people with insomnia sleep better before knee or hip surgery can reduce their pain after the operation.
-
Helping osteoarthritis patients walk with NSAIDs
This study is testing a new program that combines special exercises and occasional use of pain relief medications to help people with hip or knee osteoarthritis walk better.
-
Targeting abnormal blood flow to treat chronic joint pain in veterans
This study is testing if treating abnormal blood flow in the joints can help veterans with chronic pain and osteoarthritis feel better.
-
Low-impact exercise program for joint pain relief
This study is testing if joining low-impact exercise classes can help people with knee, hip, and ankle pain from osteoarthritis feel better and move easier.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.